Search Results - "Laliberte, Robert J."

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up by Powles, Thomas, Park, Se Hoon, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Wang, Jing, Huang, Bo, Laliberte, Robert J, di Pietro, Alessandra, Grivas, Petros

“…JCO Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432) showed that avelumab first-line (1L) maintenance…”
Get full text

Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial by Grivas, Petros, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Gurney, Howard, Bellmunt, Joaquim, Kalofonos, Haralabos, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S., Yamamoto, Yoshiaki, Petrylak, Daniel P., Sternberg, Cora N., Gupta, Shilpa, Huang, Bo, Costa, Nuno, Laliberte, Robert J., di Pietro, Alessandra, Valderrama, Begoña P., Powles, Thomas

“…In the JAVELIN Bladder 100 phase 3 trial of avelumab first-line maintenance + best supportive care (BSC) versus BSC alone in patients with advanced urothelial…”
Get full text

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance by Sridhar, Srikala S., Powles, Thomas, Climent Durán, Miguel Á., Park, Se Hoon, Massari, Francesco, Thiery-Vuillemin, Antoine, Valderrama, Begoña P., Ullén, Anders, Tsuchiya, Norihiko, Aragon-Ching, Jeanny B., Gupta, Shilpa, Petrylak, Daniel P., Bellmunt, Joaquim, Wang, Jing, Laliberte, Robert J., di Pietro, Alessandra, Costa, Nuno, Grivas, Petros, Sternberg, Cora N., Loriot, Yohann

“…In JAVELIN Bladder 100, results from analyses of overall survival and progression-free survival with avelumab first-line maintenance + best supportive care…”
Get full text

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy by Loriot, Yohann, Powles, Thomas, Climent Durán, Miguel Ángel, Sridhar, Srikala S., Bellmunt, Joaquim, Petrylak, Daniel Peter, Wang, Jing, Costa, Nuno Matos, Laliberte, Robert J, Di Pietro, Alessandra, Grivas, Petros, Sternberg, Cora N.

“…Abstract only 438 Background: Avelumab 1L maintenance is approved in the United States for patients with advanced UC that has not progressed with 1L…”
Get full text

Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer by Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Kalofonos, Haralabos, Radulovic, Sinisa, Demey, Wim, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Tsuchiya, Norihiko, Kopyltsov, Evgeny, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Petrylak, Daniel P, Laliberte, Robert J, Huang, Bo, Costa, Nuno, Blake-Haskins, John A, Grivas, Petros

“…This is a plain language summary of an article originally published in . It is about initial results (collected in October 2019) from the JAVELIN Bladder 100…”
Get full text

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer by Morse, Michael A, Bradley, Deborah A, Keler, Tibor, Laliberte, Robert J, Green, Jennifer A, Davis, Thomas A, Inman, Brant A

“…Cancer vaccines have demonstrated clinical benefit, however greater efficacy could be achieved by enhancing their immunogenicity. Owing to cancer vaccines…”
Get more information

A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides by Duvic, Madeleine, Sherman, Matthew L., Wood, Gary S., Kuzel, Timothy M., Olsen, Elise, Foss, Francine, Laliberté, Robert J., Ryan, John L., Zonno, Kristilyn, Rook, Alain H.

“…Interleukin-12 (IL-12) increases Th 1 cytokines, natural killer (NK) cells, and cytotoxic T-cell activities. Progression of mycosis fungoides is associated…”
Get full text

Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder by WEISS, Geoffrey R, O'DONNELL, Michael A, LOUGHLIN, Kevin, ZONNO, Kristilyn, LALIBERTE, Robert J, SHERMAN, Matthew L

“…Superficial transitional cell carcinoma (STCC) of the bladder is usually managed with intravesical bacille Calmette-Guerin. Recombinant human interleukin-12…”
Get full text

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy by Pérez-Valderrama, Begoña, Powles, Thomas, Sridhar, Srikala S., Caserta, Claudia, Loriot, Yohann, Gupta, Shilpa, Bellmunt, Joaquim, Sternberg, Cora N., Wang, Jing, Costa, Nuno, Laliberte, Robert J, Di Pietro, Alessandra, Park, Se Hoon, Grivas, Petros

“…4559 Background: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432), avelumab 1L maintenance + best supportive care (BSC) significantly prolonged overall…”
Get full text

Avelumab first-line (1L) maintenance + best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis by Eto, Masatoshi, Lee, Jae-Lyun, Park, Se Hoon, Tsuchiya, Norihiko, SU, Po-Jung, Chan, T.W., Desai, Chirag Jyotiker, Di Pietro, Alessandra, Wang, Jing, Laliberte, Robert J, Gao, Seasea, Gurney, Howard

“…Abstract only 486 Background: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432), avelumab 1L maintenance therapy + BSC showed significantly longer overall…”
Get full text

MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100 by Grivas, Petros, Park, Se Hoon, Voog, Eric, Kopyltsov, Evgeny, Gurney, Howard, Borges Muniz, David Queiroz, Rolland, Frédéric, Als, Anne Birgitte, Valderrama, Begoña P, Wang, Jing, Costa, Nuno, Laliberte, Robert J, di Pietro, Alessandra, Powles, Thomas, Bellmunt, Joaquim

Get full text

PD55-01 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA IN THE JAVELIN BLADDER 100 TRIAL: SUBGROUP ANALYSIS BY DURATION OF TREATMENT-FREE INTERVAL FROM END OF CHEMOTHERAPY TO START OF MAINTENANCE by Sridhar, Srikala S., Powles, Thomas, Loriot, Yohann, Climent Durán, Miguel A., Gupta, Shilpa, Tsuchiya, Norihiko, Bamias, Aristotelis, Ardizzoni, Andrea, Ullén, Anders, Huang, Bo, Costa, Nuno, Laliberte, Robert J, di Pietro, Alessandra, Sternberg, Cora N, Grivas, Petros

Get full text

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100 by Grivas, Petros, Park, Se Hoon, Voog, Eric, Kopyltsov, Evgeny, Gurney, Howard, Muniz, David Queiroz Borges, Rolland, Frederic, Als, Anne Birgitte, Valderrama, Begoña P., Wang, Jing, Costa, Nuno Matos, Laliberte, Robert J, Di Pietro, Alessandra, Powles, Thomas, Bellmunt, Joaquim

“…Abstract only 4525 Background: Avelumab 1L maintenance is approved in various countries for patients (pts) with advanced UC that has not progressed with 1L…”
Get full text

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance by Sridhar, Srikala S., Powles, Thomas, Loriot, Yohann, Climent Durán, Miguel A., Gupta, Shilpa, Tsuchiya, Norihiko, Bamias, Aristotelis, Ardizzoni, Andrea, Ullén, Anders, Huang, Bo, Costa, Nuno Matos, Laliberte, Robert J, Di Pietro, Alessandra, Sternberg, Cora N., Grivas, Petros

“…Abstract only 4527 Background: The phase 3 JAVELIN Bladder 100 trial, which enrolled patients (pts) with advanced UC that had not progressed with 1L…”
Get full text

PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL by Grivas, Petros, Bellmunt, Joaquim, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P., Gurney, Howard, Loriot, Yohann, Sridhar, Srikala S., Tsuchiya, Norihiko, Sternberg, Cora N., Aragon-Ching, Jeanny B., Petrylak, Daniel P., Blake-Haskins, John A., Laliberte, Robert J., Wang, Jing, Costa, Nuno, Powles, Thomas

Get full text

Phase 1 Study Results of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) for the Treatment of Thrombocytosis by Laliberte, Robert J., Glidden, Paul F., Hamilton, Brian L.

“…Introduction: Despite recent advances in the diagnosis and management of myeloproliferative neoplasms (MPNs), treatment of essential thrombocythemia (ET) has…”
Get full text

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial by Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Pérez-Valderrama, Begoña, Gurney, Howard, Loriot, Yohann, Sridhar, Srikala S., Tsuchiya, Norihiko, Sternberg, Cora N., Bellmunt, Joaquim, Aragon-Ching, Jeanny B., Petrylak, Daniel P., Blake-Haskins, Andy, Laliberte, Robert J, Wang, Jing, Costa, Nuno Matos, Grivas, Petros

“…Abstract only 487 Background: The phase 3 JAVELIN Bladder 100 trial (NCT02603432) showed significantly longer overall survival (OS) with avelumab + best…”
Get full text

Effects of cations that share the mitochondrial uniporter on Tc-99m-sestamibi cardiac retention by Crane, Paul D., Laliberté, Robert J., Heminway, Stuart J., Orlandi, Cesare, Thoolen, Martin J.

Get full text